Back
MHC
Manhattan Corporation Limited
🇦🇺 ASX
⛏️ MINING
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-8.50%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Manhattan Corp. Ltd. engages in the business of mineral exploration and development, and evaluation of mineral projects and corporate opportunities in the resource sector. The company is headquartered in Perth, Western Australia and currently employs 1 full-time employees. The company went IPO on 2008-01-29. The Company’s projects include Chebogue Lithium Project, Tibooburra Gold Project and Ponton Uranium Project. The Chebogue Lithium Project consists of 109 licenses covering approximately 1,200 square kilometers (km2) in the emerging hard-rock lithium jurisdiction of Nova Scotia, Canada. The project has the potential to host spodumene-bearing pegmatites. The Tibooburra Gold Project covers an area of approximately 2,200 km2, which comprises a contiguous land package of 15 granted exploration licenses that are located approximately 200 km north of Broken Hill. The firm's Ponton uranium project is located approximately 200km northeast of Kalgoorlie on the edge of the Great Victoria Desert in Western Australia. The firm has 100% control of around 460km2 of exploration tenements underlain by Tertiary palaeochannels within the Gunbarrel Basin.
📈 Performance
Price History
-11.54%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.02
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in MHC
1
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in MHC
N/A
MHC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
100%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in MHC also invest in...
Fortescue Ltd. engages in the development of iron ore deposits. The company is headquartered in Perth, Western Australia. The firm's segments include Metals and Energy. Metals segment includes exploration, development, production, processing, sale and transportation of iron ore, and the exploration for other minerals. Its metals business comprises its iron ore operations in the Pilbara as well as a pipeline of exploration projects globally including in Gabon in Africa, Latin America and Australia. The firm's metals business includes Hedland operations, Chichester Hub, Western Hub, Iron Bridge, Green Metal Project, integrated operations, Belinga Project, Blacksmith Project and Pilbara Energy Connect (PEC) project. Energy segment undertakes activities in the global development of green electricity, green hydrogen, green ammonia projects, as well as green technology development and manufacturing. Its energy business includes Arizona Hydrogen project, Holmaneset project, Pecem project and Gladstone PEM50 Project.
🙌 Performance (5Yr p.a)
3.87%
📊 Share price
$19.19 AUD
🕊️ SOCIALLY AWARE
⛏️ MINING
💰 HIGH DIVIDEND
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is developing artificial intelligence (AI) powered solutions to improve the detection and management of coronary artery disease. The company is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The firm has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians and patients.
📊 Share price
$2.45 AUD
🩺 HEALTH CARE
Want more shares? Try these...
